Core Viewpoint - Prothena (PRTA) shows significant upside potential with a mean price target of $20.5, indicating a 120.2% increase from its current trading price of $9.31 [1] Price Targets and Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $10.65, indicating variability among analysts; the lowest estimate is $8.00 (14.1% decline), while the highest is $36.00 (286.7% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates - Analysts are optimistic about Prothena's earnings prospects, as indicated by a positive trend in earnings estimate revisions; the Zacks Consensus Estimate for the current year has increased by 18.2% over the past month, with two estimates rising and no negative revisions [11][12] - Prothena holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, which supports the stock's potential upside [13] Analyst Behavior and Price Target Reliability - Analysts often set overly optimistic price targets due to business incentives, which can lead to inflated estimates; thus, investors should approach price targets with skepticism [8][10] - Despite the potential unreliability of price targets, the direction implied by them may still provide useful guidance for investors [14]

Core Viewpoint - Block (XYZ) shares have increased by 20.5% in the last four weeks, closing at $61.17, with a mean price target of $84.03 suggesting a potential upside of 37.4% [1] Price Targets and Analyst Consensus - The average of 38 short-term price targets ranges from a low of $51.00 to a high of $105.00, with a standard deviation of $11.32, indicating variability in analyst estimates [2] - The lowest estimate suggests a decline of 16.6%, while the highest indicates a potential upside of 71.7% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement direction [9] Earnings Estimates and Upside Potential - Analysts show increasing optimism about XYZ's earnings, with a positive trend in earnings estimate revisions correlating with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 21.2% over the past month, with nine estimates increasing and no negative revisions [12] - XYZ holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research indicates they rarely predict actual stock price movements [7] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8] - Investors should approach price targets with skepticism and not rely solely on them for investment decisions [10]

Core Viewpoint - Miami International Holdings, Inc. (MIAX) shows potential for upside with a mean price target of $50, indicating a 27.9% increase from the current price of $39.08 [1] Price Targets - The average price target consists of estimates ranging from a low of $41.00 to a high of $59.00, with a standard deviation of $7.53, suggesting variability in analyst predictions [2] - The lowest estimate indicates a 4.9% increase, while the highest suggests a 51% upside [2] Analyst Consensus - Analysts exhibit strong agreement on MIAX's ability to report better earnings than previously predicted, which supports the potential for stock price appreciation [4] - A positive trend in earnings estimate revisions correlates with potential stock price movements, indicating a strong relationship between earnings revisions and stock performance [11] Earnings Estimates - Over the last 30 days, three earnings estimates for MIAX have been revised upward, with no negative revisions, leading to a 4.6% increase in the Zacks Consensus Estimate [12] - MIAX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, suggesting strong potential for upside [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be prudent due to historical inaccuracies in predicting stock movements [3][7][10] - Analysts often set optimistic price targets influenced by business relationships, which can lead to inflated expectations [8]

Core Viewpoint - Newmark Group (NMRK) shares have shown a modest gain of 0.6% over the past month, closing at $14.7, with analysts suggesting a potential upside of 32.7% based on a mean price target of $19.5 [1] Price Targets and Analyst Estimates - The mean price target is derived from six short-term estimates, with a standard deviation of $1.22, indicating a range of expectations among analysts [2] - The lowest estimate stands at $18.00, suggesting a 22.5% increase, while the highest estimate predicts a 42.9% surge to $21.00 [2] - A low standard deviation signifies a strong consensus among analysts regarding the stock's price direction [2][9] Earnings Estimates and Market Sentiment - Analysts are optimistic about NMRK's earnings, with a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] - The Zacks Consensus Estimate for the current year has risen by 3.9% over the past month, with two estimates increasing and no negative revisions [12] - NMRK holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are a common tool for investors, their reliability is often questioned, as they can mislead rather than guide investment decisions [3][7] - Analysts may set overly optimistic targets due to business incentives, which can inflate expectations [8][10] - Despite the skepticism surrounding price targets, the direction implied by them can still serve as a useful guide for further research [14]

Core Viewpoint - Dave Inc. (DAVE) has shown a significant price increase of 19.6% over the past four weeks, with analysts projecting a mean price target of $313.78, indicating a potential upside of 48% from the current price of $212.02 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $24.03, where the lowest estimate is $280.00 (32.1% increase) and the highest is $347.00 (63.7% increase) [2] - A low standard deviation suggests a strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Agreement - There is a growing optimism among analysts about DAVE's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which correlates with potential stock price increases [11] - Over the last 30 days, three earnings estimates have been revised upward, resulting in a 7% increase in the Zacks Consensus Estimate [12] Zacks Rank and Investment Potential - DAVE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside in the near term [13]

Core Viewpoint - McGraw Hill, Inc. (MH) shares have increased by 9.4% recently, with analysts suggesting a potential upside of 48.6% based on a mean price target of $20.67 [1] Price Targets and Analyst Estimates - The mean estimate consists of 12 short-term price targets, with a standard deviation of $2.61, indicating variability among analysts [2] - The lowest estimate is $17.00, suggesting a 22.2% increase, while the highest estimate is $27.00, indicating a potential surge of 94.1% [2] - Analysts' price targets can often mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism regarding MH's earnings prospects, with a strong consensus on higher EPS estimates, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 18.7% over the past month, with five estimates increasing and no negative revisions [12] - MH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While consensus price targets may not be reliable for predicting the extent of gains, they can provide a useful guide for the direction of price movement [14]

Group 1 - DFIN closed at $49.64, with a 2.8% gain over the past four weeks, and analysts set a mean price target of $64.33, indicating a 29.6% upside potential [1] - The mean estimate includes three short-term price targets with a standard deviation of $6.66, where the lowest estimate is $57.00 (14.8% increase) and the highest is $70.00 (41% increase) [2] - Analysts show strong agreement on DFIN's ability to report better earnings, with a positive trend in earnings estimate revisions, which is a strong indicator of potential upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 30% over the past month, with one estimate going higher and no negative revisions [12] - DFIN holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be reliable for predicting the extent of gains, it does provide a good directional guide for price movement [14]

Core Viewpoint - U.S. Physical Therapy (USPH) shows potential for significant upside, with a mean price target of $105.33 indicating a 26.5% increase from its current price of $83.25 [1] Price Targets - The average price target consists of six estimates ranging from a low of $98.00 to a high of $113.00, with a standard deviation of $5.92, suggesting a consensus among analysts [2] - The lowest estimate indicates a 17.7% increase, while the highest suggests a 35.7% upside [2] Analyst Sentiment - Analysts are increasingly optimistic about USPH's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has risen by 2.4% over the past month, with two estimates increasing and no negative revisions [12] Zacks Rank - USPH holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be prudent due to potential biases among analysts [3][10] - A low standard deviation in price targets indicates a high degree of agreement among analysts, which can be a starting point for further research [9]

Core Viewpoint - Slide Insurance Holdings, Inc. (SLDE) has seen a 10.3% increase in share price over the past four weeks, closing at $19, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $24.4, representing a 28.4% upside [1] Price Targets and Analyst Estimates - The mean estimate consists of five short-term price targets with a standard deviation of $2.88, where the lowest estimate of $22.00 indicates a 15.8% increase, and the highest estimate of $29.00 suggests a 52.6% increase [2] - A low standard deviation among price targets indicates a high degree of agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about SLDE's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - The Zacks Consensus Estimate for the current year has risen by 21.3% over the past month, with two estimates increasing and no negative revisions [12] - SLDE holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the extent of SLDE's potential gains, the implied direction of price movement appears to be a useful guide [14]

Group 1 - Shares of Privia Health (PRVA) have increased by 8.9% over the past four weeks, closing at $24.91, with a mean price target of $31.25 indicating a potential upside of 25.5% [1] - The mean estimate consists of 20 short-term price targets with a standard deviation of $2.99, where the lowest estimate is $23.00 (7.7% decline) and the highest is $37.00 (48.5% increase) [2] - Analysts show strong agreement in revising earnings estimates higher, which correlates with potential stock price movements, as indicated by a 1.7% increase in the Zacks Consensus Estimate for the current year [11][12] Group 2 - PRVA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, suggesting a strong potential upside [13] - While price targets are often viewed as misleading, the direction indicated by the consensus price target may serve as a useful guide for investors [10][14] - Analysts' price targets can be influenced by business relationships, leading to potentially inflated estimates, but a low standard deviation among targets suggests a consensus on price movement direction [8][9]